Sorenson John Bradley's Form 4 filing
Boston Scientific Corp (BSX) · filed Nov 12, 2024
- Accession no.
- 0001225208-24-009878
- Filed
- Nov 12, 2024
- Trade date
- Nov 8, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.68M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sorenson John BradleyCIK 0001629277 | Officer (EVP, Global Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2024 | Common Stock | MOption exerciseAcquired | +17,362 | $24.55 | +$426,237.1 | 70,286 | Direct | |
| Nov 8, 2024 | Common Stock | SSaleDisposed | −30,580 | $87.66F2 | −$2,680,642.8 | 39,706 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2024 | Common Stock | MOption exerciseDisposed | −17,362 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.324 to $87.94, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.